Aurinia Pharmaceuticals Inc (AUPH)
Featured in
Financially Strong Value
Aurinia Pharmaceuticals Inc. is a NASDAQ-listed common stock of a biopharmaceutical company focused on therapies for people living with autoimmune diseases that have high unmet medical needs in the United States and Japan. The company markets LUPKYNIS (voclosporin), an oral treatment for adults with active lupus nephritis, and is developing aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand, for potential use in autoimmune diseases. Founded in 1993, Aurinia is headquartered in Edmonton, Canada.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AUPH
|
$19.31
|
15.8% Upside
|
Fair
|
$17.86
|
7.1% Upside
|
Fair
|
Excellent
|
0.0%
|
October 29, 2026
|
7.1x
|
3.6x
|
7.1x
|
2.218 B
|
1.839 B
|
2.8%
|
97.1%
|
9.5
|
55.7%
|
